PEOPLE ON THE MOVE
Merck KGaA
Merck KGaA has promoted its head of immuno-oncology research to senior vice president. Laszlo Radvanyi has spent the last ten years researching tumour-infiltrating lymphocytes (TILs) and more than 25 years studying cellular and molecular immunology. He will be based in Billerica, Massachusetts.
Merck KGaA (Merck Serono) is currently trialling its lead anti-PD-L1 candidate avelumab for 15 types of cancer.
Before joining Merck, Radvanyi served as chief scientific officer at Lion Biotechnologies in Tampa, Florida, where he was responsible for developing new technologies for next-generation TILs. He also worked on melanomas and breast cancer at MD Anderson Cancer Center in Houston, Texas.
Radvanyi has published more than 100 peer-reviewed and invited research articles and serves as an adjunct member of faculty in the Department of Immunology at H. Lee Moffitt Cancer Center in Tampa, Florida.